An interventional study of Reduction mammaplasty in Sexual Function and Depression, sponsored by Daniela Francescato Veiga. Completed at 1 site in Brazil. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-06.
Sponsored by Daniela Francescato Veiga · Not applicable, Interventional, and Health services research
The aim of this study is to determine the impact of reduction mammaplasty on sexuality and depression predictors in women with macromastia.
Breast hypertrophy is a common condition among women. Reduction mammaplasty is an effective and well established procedure performed for the relief discomfort associated with breast hypertrophy. Female breasts play an important role in sexuality, thus, the main purpose of this study is to determine whether reduction mammaplasty could influence sexual function and depression predictors on women with breast hypertrophy.
8,057 studies on the registry are indexed under Depression; 1,643 are open to participants now.
This study's enrollment of 60 is below the median of 84 across 6,718 interventional studies indexed under Depression.
Browse Depression studies →Daniela Francescato Veiga is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
Procedure: Reduction mammaplasty
Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
Also known as: Breast reduction
Sexual function
Sexual function will be assessed by the Female Sexual Function Index (FSFI), pre and 6 months postoperatively.
Time frame: 6 months
depression predictors
Depression predictors will me assessed by the Beck Depression Inventory (BDI) pre- and 6 months postoperatively.
Time frame: 6 months
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daniela Francescato Veiga